Lung adenocarcinoma metastasis within a pituitary neuroendocrine tumor: a case report with review of literature

• Published in: Endocrine Journal 2024, Vol.71(3), pp.295-303
• Main Authors: Suzuki, Koji, Tahara, Shigeyuki, Hattori, Yujiro, Teramoto, Shinichiro, Ishisaka, Eitaro, Inomoto, Chie, Osamura, Robert Yoshiyuki, Morita, Akio, Murai, Yasuo
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Cancer; Case reports; Chemotherapy; Collision tumor; Colon cancer; Gadolinium; Genetic screening; Lung adenocarcinoma; Magnetic resonance imaging; Metastases; Metastasis; Molecular-targeted therapy; Neuroendocrine tumors; Pituitary (anterior); Pituitary neuroendocrine tumor; Radiation therapy; Surgery; Vision
• ISSN: 0918-8959; 1348-4540
• DOI: 10.1507/endocrj.EJ23-0372

Collision tumors involving the metastasis of malignant neoplasms to pituitary neuroendocrine tumors (PitNETs) are extremely rare. We herein report a case involving a patient with lung adenocarcinoma metastasis within a PitNET who exhibited relatively rapid progression of neurological symptoms. A 75-year-old man who underwent tumor resection 36 and 18 years prior to presentation for bladder and colon cancer, respectively, without recurrence presented with bitemporal hemianopsia, ptosis, and diplopia of the right eye. Subsequent magnetic resonance imaging (MRI) revealed a tumor 3.2 cm in diameter that extended from the anterior pituitary gland to the suprasellar region. Gadolinium-enhanced MRI of the tumor showed heterogeneous contrast enhancement. Considering the relatively rapid progression of neurological symptoms, semi-emergency endoscopic endonasal transsphenoidal surgery was performed. Histopathological examination revealed a group of thyroid transcription factor-1- and napsin A-positive papillary proliferating cells intermingled with α-subunit- and steroidogenic factor-1-positive PitNET cells. Thus, the patient was diagnosed with lung adenocarcinoma metastasis within a gonadotroph PitNET. Genetic testing revealed the presence of an EGFR (Ex-19del) mutation, after which chemotherapy was initiated. Additional stereotactic radiotherapy was performed for the residual tumor in the sella turcica. With continued chemotherapy, good control of both the primary and metastatic tumors was noted after 24 months after surgery. Cases of malignant neoplasm metastasis within a PitNET are difficult to diagnose. In the case of a sella turcica tumor with relatively rapid progression of neurological symptoms, early surgical intervention is recommended given the possibility of a highly proliferative tumor and the need to obtain pathologic specimens.